Methods of treatment with Syk inhibitors
View Patent ↗The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.
1. A method for inhibiting restenosis in a patient undergoing a vascular intervention, said method comprising:
treating said patient with an intravascular device having a coating, said coating comprising a polymer and a Syk inhibitor, wherein said coating is applied to said intravascular device; wherein said Syk inhibitor is present in an amount sufficient to inhibit restenosis, thrombosis, and inflammation in a patient undergoing said vascular intervention.
2. The method of claim 1 , wherein said intravascular device is selected from the group consisting of a stent, a balloon catheter, an autologous venous/arterial graft, a prosthetic venous/arterial graft, a vascular catheter, and a vascular shunt.
3. The method of claim 2 , wherein said intravascular device is a stent.
4. The method of claim 1 , wherein said vascular intervention is angioplasty or a stent procedure.
5. A method for inhibiting restenosis, thrombosis, and inflammation in a patient undergoing a vascular intervention, said method comprising:
treating said patient with an intravascular device having a coating, said coating comprising a polymer and a Syk inhibitor, wherein said coating is applied to said intravascular device; wherein said Syk inhibitor is present in an amount sufficient to inhibit restenosis, thrombosis, and inflammation in a patient undergoing said vascular intervention.
6. The method of claim 5 , wherein said intravascular device is selected from the group consisting of a stent, a balloon catheter, an autologous venous/arterial graft, a prosthetic venous/arterial graft, a vascular catheter, and a vascular shunt.
7. The method of claim 6 , wherein said intravascular device is a stent.
8. The method of claim 5 , wherein said vascular intervention is angioplasty or a stent procedure.
9. The method of claim 5 , wherein said Syk inhibitor blocks the adhesion of platelets to the lumen of a blood vessel.
10. The method of claim 5 , wherein said Syk inhibitor blocks the adhesion of leukocytes to the lumen of a blood vessel.
11. The method of claim 1 or 5 , wherein said Syk inhibitor is selected from the group consisting of a purine-2-benzamine derivative, a pyrimidine-5-carboxamide derivative, a 1,6-naphthyridine derivative, BAY 61-3606, piceatannol, 3,4-dimethyl-10-(3-aminopropyl)-9-acridone oxalate), and combinations thereof.